症状性子宫腺肌病保留子宫干预后复发与再干预风险:系统综述与Meta分析
该系统综述与Meta分析纳入42项单臂回顾性或前瞻性研究、共5877例患者,评估子宫腺肌病保留子宫治疗后的复发与再干预风险。子宫腺肌病病灶切除术、子宫动脉栓塞术(UAE)和影像引导热消融的复发率分别为12.6%、29.5%和10.0%,再干预率分别为2.6%、12.8%和8.2%。作者认为UAE复发和再干预率较高,但UAE患者子宫更大、腺肌病病灶更大,选择偏倚可能影响结果。
要点
- 腺肌病病灶切除术后复发率12.6%(95%CI 8.9-16.4%),再干预率2.6%(95%CI 0.9-4.3%)。
- UAE后复发率29.5%(95%CI 17.4-41.5%),再干预率12.8%(95%CI 7.2-18.4%)。
- 影像引导热消融后复发率10.0%(95%CI 5.6-14.4%),再干预率8.2%(95%CI 4.6-11.9%)。
核心结论
- 保留子宫技术治疗子宫腺肌病成功,再干预率低;UAE复发和再干预率高于其他技术,但UAE患者子宫和腺肌病病灶更大,选择偏倚可能影响结果;未来需要更多更大样本的随机对照试验。
研究设计与样本
- 系统综述与Meta分析,检索Web of Science、MEDLINE、Cochrane Library、EMBASE、ClinicalTrials.gov和Google Scholar从2000年1月至2022年1月,纳入42项单臂回顾性和前瞻性研究、共5877例患者。
主要发现
- 腺肌病病灶切除术后复发率12.6%(95%CI 8.9-16.4%),再干预率2.6%(95%CI 0.9-4.3%)。
- UAE后复发率29.5%(95%CI 17.4-41.5%),再干预率12.8%(95%CI 7.2-18.4%)。
- 影像引导热消融后复发率10.0%(95%CI 5.6-14.4%),再干预率8.2%(95%CI 4.6-11.9%)。
关键数值与推荐
- 复发定义为症状(痛经或月经过多)在显著或完全缓解后重现,或超声或磁共振成像证实的腺肌病病灶重现。
- 结局指标以百分比频率和95%CI合并呈现。
临床怎么用
- 原文未据此给出推荐。
局限性
- UAE患者子宫更大、腺肌病病灶更大,选择偏倚可能影响结果。
- 未来需要更多更大样本的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk of recurrence and reintervention after uterine-sparing treatment options for symptomatic adenomyosis, including adenomyomectomy, uterine artery embolization (UAE), and image-guided thermal ablation. DATA SOURCES: We searched electronic databases such as Web of Science, MEDLINE, Cochrane Library, EMBASE, ClinicalTrials.gov , and Google Scholar from January 2000 to January 2022. The search was conducted using the following search terms: "adenomyosis," "recurrence," "reintervention," "relapse," and "recur." METHODS OF STUDY SELECTION: All studies that described the risk of recurrence or reintervention after uterine-sparing interventions for symptomatic adenomyosis were reviewed and screened according to the eligibility criteria. Recurrence was defined as the reappearance of symptoms (painful menses or heavy menstrual bleeding) after significant or complete remission, or the reappearance of adenomyotic lesions confirmed by ultrasonography or magnetic resonance imaging. TABULATION, INTEGRATION, AND RESULTS: The outcome measures were presented as the frequency with percentage and pooled with 95% CI. A total of 42 studies (single-arm retrospective and prospective studies) that represented 5,877 patients were included. The recurrence rates after adenomyomectomy, UAE, and image-guided thermal ablation were 12.6% (95% CI 8.9-16.4%), 29.5% (95% CI 17.4-41.5%), and 10.0% (95% CI 5.6-14.4%), respectively. The reintervention rates were 2.6% (95% CI 0.9-4.3%), 12.8% (95% CI 7.2-18.4%), and 8.2% (95% CI 4.6-11.9%) after adenomyomectomy, UAE, and image-guided thermal ablation, respectively. Subgroup analysis and sensitivity analysis were performed, and the heterogeneity was reduced in several analyses. CONCLUSION: Uterine-sparing techniques were successful in treating adenomyosis with low reintervention rates. Uterine artery embolization had higher recurrence and reintervention rates than other techniques; however, patients treated with UAE had larger uteri and larger adenomyosis, indicating that selection bias may influence these results. More randomized controlled trials with a larger population are needed in the future. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42021261289.
引用
- Liu L, Tian H, Lin D, et al. Risk of Recurrence and Reintervention After Uterine-Sparing Interventions for Symptomatic Adenomyosis: A Systematic Review and Meta-Analysis. Obstet Gynecol. 2023. PMID: 36897132. doi:10.1097/AOG.0000000000005080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。